著者検索結果

1

Endpoints for Assessing Drug Activity in Clinical Trials 著者: Richard Pazdur

出版事項 2008

全文の入手全文の入手
Revisão

お気に入りに追加

保存先:
2

Re-Evaluating Eligibility Criteria for Oncology Clinical Trials: Analysis of Investigational New Drug Applications in 2015 著者: Susan Jin, Richard Pazdur, Rajeshwari Sridhara

出版事項 2017

全文の入手
Artigo

お気に入りに追加

保存先:
3

Approval Summary: Pemetrexed in the Initial Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer 著者: Martin H. Cohen, Robert Justice, Richard Pazdur

出版事項 2009

全文の入手全文の入手
Artigo

お気に入りに追加

保存先:
4

FDA Drug Approval Summary: Alemtuzumab as Single-Agent Treatment for B-Cell Chronic Lymphocytic Leukemia 著者: Suzanne Demko, Jeffrey Summers, Patricia Keegan, Richard Pazdur

出版事項 2008

全文の入手全文の入手
Artigo

お気に入りに追加

保存先:
5

Rare Cancer Trial Design: Lessons from FDA Approvals 著者: Himabindu Gaddipati, Ke Liu, Anne Pariser, Richard Pazdur

出版事項 2012

全文の入手
Artigo

お気に入りに追加

保存先:
6

U.S. Food and Drug Administration Drug Approval Summary: Conversion of Imatinib Mesylate (STI571; Gleevec) Tablets from Accelerated Approval to Full Approval 著者: Martin H. Cohen, John R. Johnson, Richard Pazdur

出版事項 2005

全文の入手全文の入手
Artigo

お気に入りに追加

保存先:
7

FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease 著者: Min Lu, Martin H. Cohen, Dwaine Rieves, Richard Pazdur

出版事項 2010

全文の入手全文の入手
Artigo

お気に入りに追加

保存先:
8

United States Food and Drug Administration Approval Summary: Bortezomib for the Treatment of Progressive Multiple Myeloma after One Prior Therapy 著者: Robert C. Kane, Ann T. Farrell, Rajeshwari Sridhara, Richard Pazdur

出版事項 2006

全文の入手全文の入手
Artigo

お気に入りに追加

保存先:
9

FDA Drug Approval Summary: Bevacizumab plus Interferon for Advanced Renal Cell Carcinoma 著者: Jeff Summers, Martin H. Cohen, Patricia Keegan, Richard Pazdur

出版事項 2010

全文の入手
Artigo

お気に入りに追加

保存先:
10

Velcade®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy 著者: Robert C. Kane, Peter Bross, Ann T. Farrell, Richard Pazdur

出版事項 2003

全文の入手全文の入手
Revisão

お気に入りに追加

保存先:
11

FDA Drug Approval Summary: Bevacizumab Plus FOLFOX4 as Second-Line Treatment of Colorectal Cancer 著者: Martin H. Cohen, Joe Gootenberg, Patricia Keegan, Richard Pazdur

出版事項 2007

全文の入手全文の入手
Artigo

お気に入りに追加

保存先:
12

Approval Summary: Pemetrexed Maintenance Therapy of Advanced/Metastatic Nonsquamous, Non-Small Cell Lung Cancer (NSCLC) 著者: Martin H. Cohen, Patricia Cortazar, Robert Justice, Richard Pazdur

出版事項 2010

全文の入手
Artigo

お気に入りに追加

保存先:
13

Approval Summary: Imatinib Mesylate in the Treatment of Metastatic and/or Unresectable Malignant Gastrointestinal Stromal Tumors 著者: Martin H. Cohen, Ann T. Farrell, Robert Justice, Richard Pazdur

出版事項 2009

全文の入手全文の入手
Artigo

お気に入りに追加

保存先:
14

FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors 著者: Leigh Marcus, Steven J. Lemery, Patricia Keegan, Richard Pazdur

出版事項 2019

全文の入手
Artigo

お気に入りに追加

保存先:
15

FDA Drug Approval Summary: Nelarabine (Arranon®) for the Treatment of T-Cell Lymphoblastic Leukemia/Lymphoma 著者: Martin H. Cohen, John R. Johnson, Robert Justice, Richard Pazdur

出版事項 2008

全文の入手全文の入手
Artigo

お気に入りに追加

保存先:
16

FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme 著者: Martin H. Cohen, Yuan Li Shen, Patricia Keegan, Richard Pazdur

出版事項 2009

全文の入手全文の入手
Artigo

お気に入りに追加

保存先:
17

FDA Drug Approval Summaries: Fulvestrant 著者: Peter Bross, Martin H. Cohen, Grant A. Williams, Richard Pazdur

出版事項 2002

全文の入手全文の入手
Artigo

お気に入りに追加

保存先:
18

Low-dose continuous infusion 5-fluorouracil. Evaluation in advanced breast carcinoma 著者: S. Huan, Richard Pazdur, Amnuay Singhakowinta, Bohumil A. Samal, Vainutis K. Vaitkevicus

出版事項 1989

全文の入手全文の入手
Artigo

お気に入りに追加

保存先:
19

Prospective evaluation of adrenal insufficiency in patients with adrenal metastasis 著者: Bruce G. Redman, Richard Pazdur, Alkis P. Zingas, Rene D. Loredo

出版事項 1987

全文の入手全文の入手
Artigo

お気に入りに追加

保存先:
20

Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non–Small Cell Lung Cancer 著者: Dickran Kazandjian, Yutao Gong, Patricia Keegan, Richard Pazdur, Gideon M. Blumenthal

出版事項 2019

全文の入手全文の入手
Artigo

お気に入りに追加

保存先:

検索結果 - Richard Pazdur

Endpoints for Assessing Drug Activity in Clinical Trials 著者: Richard Pazdur

Re-Evaluating Eligibility Criteria for Oncology Clinical Trials: Analysis of Investigational New Drug Applications in 2015 著者: Susan Jin, Richard Pazdur, Rajeshwari Sridhara

Approval Summary: Pemetrexed in the Initial Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer 著者: Martin H. Cohen, Robert Justice, Richard Pazdur

FDA Drug Approval Summary: Alemtuzumab as Single-Agent Treatment for B-Cell Chronic Lymphocytic Leukemia 著者: Suzanne Demko, Jeffrey Summers, Patricia Keegan, Richard Pazdur

Rare Cancer Trial Design: Lessons from FDA Approvals 著者: Himabindu Gaddipati, Ke Liu, Anne Pariser, Richard Pazdur

U.S. Food and Drug Administration Drug Approval Summary: Conversion of Imatinib Mesylate (STI571; Gleevec) Tablets from Accelerated Approval to Full Approval 著者: Martin H. Cohen, John R. Johnson, Richard Pazdur

FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease 著者: Min Lu, Martin H. Cohen, Dwaine Rieves, Richard Pazdur

United States Food and Drug Administration Approval Summary: Bortezomib for the Treatment of Progressive Multiple Myeloma after One Prior Therapy 著者: Robert C. Kane, Ann T. Farrell, Rajeshwari Sridhara, Richard Pazdur

FDA Drug Approval Summary: Bevacizumab plus Interferon for Advanced Renal Cell Carcinoma 著者: Jeff Summers, Martin H. Cohen, Patricia Keegan, Richard Pazdur

Velcade®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy 著者: Robert C. Kane, Peter Bross, Ann T. Farrell, Richard Pazdur

FDA Drug Approval Summary: Bevacizumab Plus FOLFOX4 as Second-Line Treatment of Colorectal Cancer 著者: Martin H. Cohen, Joe Gootenberg, Patricia Keegan, Richard Pazdur

Approval Summary: Pemetrexed Maintenance Therapy of Advanced/Metastatic Nonsquamous, Non-Small Cell Lung Cancer (NSCLC) 著者: Martin H. Cohen, Patricia Cortazar, Robert Justice, Richard Pazdur

Approval Summary: Imatinib Mesylate in the Treatment of Metastatic and/or Unresectable Malignant Gastrointestinal Stromal Tumors 著者: Martin H. Cohen, Ann T. Farrell, Robert Justice, Richard Pazdur

FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors 著者: Leigh Marcus, Steven J. Lemery, Patricia Keegan, Richard Pazdur

FDA Drug Approval Summary: Nelarabine (Arranon®) for the Treatment of T-Cell Lymphoblastic Leukemia/Lymphoma 著者: Martin H. Cohen, John R. Johnson, Robert Justice, Richard Pazdur

FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme 著者: Martin H. Cohen, Yuan Li Shen, Patricia Keegan, Richard Pazdur

FDA Drug Approval Summaries: Fulvestrant 著者: Peter Bross, Martin H. Cohen, Grant A. Williams, Richard Pazdur

Low-dose continuous infusion 5-fluorouracil. Evaluation in advanced breast carcinoma 著者: S. Huan, Richard Pazdur, Amnuay Singhakowinta, Bohumil A. Samal, Vainutis K. Vaitkevicus

Prospective evaluation of adrenal insufficiency in patients with adrenal metastasis 著者: Bruce G. Redman, Richard Pazdur, Alkis P. Zingas, Rene D. Loredo

Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non–Small Cell Lung Cancer 著者: Dickran Kazandjian, Yutao Gong, Patricia Keegan, Richard Pazdur, Gideon M. Blumenthal

検索ツール:

関連主題